**Core Concept**
Dopaminergic agonists are medications that mimic the action of dopamine, a neurotransmitter involved in motor control and reward. In the context of Parkinson's disease, dopaminergic agonists are used to replace dopamine in the brain, alleviating symptoms such as tremors, rigidity, and bradykinesia.

**Why the Correct Answer is Right**
Selegiline is a monoamine oxidase B (MAO-B) inhibitor, a type of medication that increases the levels of dopamine in the brain by preventing its breakdown. However, unlike dopaminergic agonists, selegiline does not directly stimulate dopamine receptors. Instead, it works indirectly by increasing the availability of dopamine for the brain to use. This makes selegiline a unique medication that is often classified as a selective MAO-B inhibitor or a dopamine precursor, rather than a dopaminergic agonist.

**Why Each Wrong Option is Incorrect**
**Option A:** Bromocriptine is a dopamine D2 receptor agonist, which means it directly stimulates dopamine receptors in the brain, making it a dopaminergic agonist used for Parkinson's disease treatment.
**Option B:** Ropinirole is a dopamine D2 and D3 receptor agonist, similar to bromocriptine, and is used to treat Parkinson's disease symptoms.
**Option C:** Pramipexole is also a dopamine D2 and D3 receptor agonist, making it another dopaminergic agonist used for Parkinson's disease treatment.

**Clinical Pearl / High-Yield Fact**
Remember the difference between dopaminergic agonists and monoamine oxidase inhibitors (MAOIs): dopaminergic agonists directly stimulate dopamine receptors, while MAOIs, like selegiline, increase dopamine availability by preventing its breakdown. This distinction is crucial for understanding the mechanism of action of various medications used in Parkinson's disease treatment.

**✓ Correct Answer: D. Selegiline**